RyboDyn Secures $1.3M Defense Grant for Lung Cancer Research

The funding, issued through the Congressionally Directed Medical Research Programs, supports the expansion of RyboDyn’s preclinical pipeline. The company utilizes its proprietary AI platform, RyboCypher, to decode the so-called dark proteome—a vast landscape of cryptic proteins that conventional sequencing methods often miss. By shifting the focus from existing, well-characterized targets to these overlooked biological markers, the firm aims to create first-in-class treatments that are both highly specific to cancer cells and absent in healthy tissue.

RyboDyn’s approach centers on its CypherAtlas knowledgebase, which currently catalogs over 6 million dark RNAs and 10,000 cancer-specific peptides derived from more than 2,000 patient samples. The newly funded programs focus on two specific cell-surface targets prevalent in lung cancer, which will now undergo rigorous in vivo proof-of-concept testing. This research addresses a critical clinical gap for the veteran community, where exposure to occupational hazards such as burn pits and asbestos has historically elevated lung cancer risks. By discovering therapeutic targets directly from patient biology, the company seeks to bypass the high failure rates that plague traditional oncology drug development.